Triple-Negative Breast Cancer (TNBC) Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01676753Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerTreatment